Viatris is a global healthcare company specializing in the development, manufacturing, and marketing of generic and complex medicines, with a broad product portfolio and a large patient reach.

# Viatris Company Summary

## Business Focus
- Viatris is a healthcare company that develops, manufactures, and markets pharmaceuticals, including generic and specialty medicines.
- The company operates globally across various markets, focusing on delivering affordable medicines and healthcare solutions.

## Key Operations & Strategic Focus
- Maintains a diversified portfolio of more than 1,000 products spanning multiple therapeutic areas.
- Emphasizes growth through expanding its innovative portfolio, including complex and difficult-to-formulate products like modified-release and injectable therapies.
- Focuses on building a large, diversified base business across generics and off-patent brands.
- Develops and advances a pipeline that includes dosage forms like oral solids, transdermals, injectables, inhalation, and others.
- Engages in acquisitions and strategic partnerships to increase product offerings and develop new therapies, including in immunology and cardiovascular areas.

## Financial Highlights (2024)
- Total revenue: **$14.7 billion**
- U.S. GAAP net loss: **$(634) million**
- Adjusted EBITDA: **$4.7 billion**
- U.S. GAAP diluted EPS: **$(0.53) per share**
- Adjusted EPS: **$2.65 per share**
- Net cash provided by operating activities: **$2.3 billion**
- Free cash flow: **$2.0 billion** (including ~$650 million in transaction-related costs)
- Debt reduction: Paid down approximately **$3.7 billion** of debt
- Gross leverage ratio at year-end: **2.9x** (compared to a targeted around 3.0x)
- Capital returned to shareholders: **$825 million** through dividends and share repurchases
- Supporting approximately **1 billion patients** worldwide
  
## Operations & Divestitures
- Completed divestitures of several business segments:
  - Women's healthcare business, including contraceptive products, to Insud Pharma.
  - API business in India, sold to Matrix Pharma.
  - Over-the-counter (OTC) business, sold to Cooper Consumer Health.
- Maintains select rights for products like Viagra® and Dymista® in certain markets.

## Research & Development
- Focus on developing complex products and expanding patent-protected assets.
- Made acquisitions such as rights to Phase 3 assets for selatogrel and cenerimod from Idorsia.
- Announced licensing agreements, including sotagliflozin for heart failure and diabetes.

## Customer Base
- Supplies high-quality medicines to approximately **1 billion patients globally**.

## Manufacturing & Product Types
- Produces medicines in various dosage forms:
  - Oral solid dosage
  - Transdermal patches
  - Injectables
  - Inhalation therapies
- Avoids commodity products; instead, invests in complex, hard-to-formulate treatments.

## Market & Global Reach
- Operates worldwide with facilities and markets across developed nations, emerging markets, Japan, Australia, New Zealand, and Greater China.
- Provides healthcare solutions in over a dozen therapeutic areas with a focus on affordability and accessibility.

## Corporate Governance & Leadership
- Led by CEO Scott A. Smith since April 2023.
- Senior management includes executives with extensive healthcare industry experience.
- The Board of Directors combines expertise in management, finance, healthcare, legal, and governance, with a focus on strategy, risk oversight, and sustainability.

## Summary
Viatris is a large, diversified global healthcare company specializing in generics and complex medicines, with a broad product portfolio, a significant patient reach, and ongoing investments in innovation and strategic acquisitions. It maintains a strong financial position, prioritizes cost management, and actively manages risks and corporate governance to support long-term growth.

Viatris Inc. is a global healthcare company that produces and distributes a wide range of generic and branded medications, ensuring access to high-quality medicines for patients worldwide.

### Company Overview: Viatris Inc.

**Business Description:**
Viatris Inc. is a global healthcare company formed through the merger of Mylan and Pfizer's Upjohn business. The company is dedicated to producing and distributing a wide range of generic and branded medications, biosimilars, and over-the-counter (OTC) products. Viatris is committed to ensuring access to high-quality medicines for patients worldwide, aiming to empower people and communities to live healthier lives.

**Key Operations:**
- Viatris operates in various therapeutic areas, including infectious diseases, oncology, cardiovascular health, and women's health.
- The company has a diverse product portfolio with over 250 medicines listed on the World Health Organization's Essential Medicines List.
- Viatris also invests in research and development (R&D), focusing on innovative product formulations and delivery methods.

**Customer Base:**
- Viatris supplies high-quality medicines to approximately **1 billion patients globally**.
- The company's products cater to a wide demographic, addressing various health conditions across different markets.

**Financial Overview:**
- **Revenue**: For the fiscal year ended December 31, 2023, Viatris reported total revenues of **$15.4 billion**.
- **Net Income**: The U.S. GAAP net earnings for the same period were **$54.7 million**.
- **Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization)**: Viatris achieved adjusted EBITDA of **$5.1 billion** in 2023.
- **Cash Flow**: The net cash provided by operating activities totaled **$2.8 billion**, with free cash flow amounting to **$2.4 billion**.

**Workforce:**
- Viatris employs approximately **40,000 individuals** globally, with a diverse and skilled workforce committed to fulfilling the company's mission of providing access to health solutions. 

**Sustainability and Corporate Responsibility:**
- Viatris emphasizes corporate environmental and social responsibility, aiming to sustain its business operations while being mindful of its impact on society and the environment.
- The company has a governance structure that includes oversight of its sustainability initiatives and risk management processes.

**Strategic Goals:**
- The company's strategic vision includes moving up the value chain by focusing on more complex and innovative products, enhancing market access, and increasing its portfolio of higher-margin offerings.
- Viatris is actively divesting non-core assets and streamlining operations to maximize shareholder value.

This detailed overview encapsulates Viatris Inc.'s commitment to healthcare, operational scale, financial performance, and strategic growth initiatives.

Viatris Inc

10-K / April 30, 2025

10-K / April 26, 2024

10-K / April 30, 2025

Viatris Company Summary

Business Focus

Key Operations & Strategic Focus

Financial Highlights (2024)

Operations & Divestitures

Research & Development

Customer Base

Manufacturing & Product Types

Market & Global Reach

Corporate Governance & Leadership

Summary